Published in Case Rep Hematol on December 26, 2012
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res (2010) 2.85
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol (2010) 2.46
Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer (2005) 2.30
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology (2011) 1.74
Long-term complications of lymphoma and its treatment. J Clin Oncol (2011) 1.73
Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect (2009) 1.39
Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer (2010) 1.15
Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat (2004) 1.07
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol (2011) 1.03
Risk of second malignant neoplasm among patients with lymphoma. J Clin Oncol (2011) 0.80
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol (2008) 1.71
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
Questionable validity of cardiac risk score on the basis of the NSABP B-31 model. J Clin Oncol (2013) 1.39
The extra cytoplasmic function sigma factor sigma(E) is essential for Mycobacterium tuberculosis virulence in mice. Infect Immun (2004) 1.37
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ScientificWorldJournal (2010) 1.21
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One (2013) 1.14
Thyroid metastasis of clear cell renal carcinoma: Report of a case. Diagn Cytopathol (2009) 1.13
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Pseudotumoral appearance of peliosis hepatis. AJR Am J Roentgenol (2005) 1.02
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol (2004) 1.01
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer (2013) 1.00
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Spindle-cell tumours of the larynx: diagnostic pitfalls. A case report and review of the literature. Acta Otolaryngol (2003) 1.00
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood (2003) 0.98
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics (2009) 0.96
Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One (2013) 0.93
Thyroid metastases from renal cell carcinoma: review of the literature. ScientificWorldJournal (2010) 0.92
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Eur J Pharmacol (2011) 0.92
Peritoneal carcinomatosis of colorectal origin. World J Gastrointest Oncol (2010) 0.92
Applications of genomics in NSCLC. Lung Cancer (2005) 0.90
Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev (2009) 0.89
Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice. Shock (2012) 0.88
Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. Eur J Cancer (2006) 0.88
Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol (2011) 0.87
Diffuse intra-abdominal clear cell myomelanocytic tumor: report of an unusual presentation of "PEComatosis" simulating peritoneal mesothelioma. Ann Diagn Pathol (2006) 0.87
Detection of human papillomavirus in temporal bone inverted papilloma by polymerase chain reaction. Acta Otolaryngol (2003) 0.86
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol (2010) 0.86
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. Eur J Pharmacol (2010) 0.86
Dasatinib induces a response in chronic lymphocytic leukemia. Blood (2009) 0.86
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncol (2013) 0.84
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip (2013) 0.84
Squamous cell carcinoma of the larynx with osteosarcoma-like stromal metaplasia. Acta Otolaryngol (2004) 0.83
Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine (2004) 0.83
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. Cancer Invest (2008) 0.82
Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res (2006) 0.82
Malignant perivascular epithelioid cell tumor of the esophagus. Case Rep Pathol (2012) 0.82
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. J Neurooncol (2008) 0.82
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Rev Respir Med (2011) 0.81
Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study. Lung Cancer (2002) 0.81
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med (2014) 0.81
Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res (2007) 0.80
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide. J Neurooncol (2007) 0.80
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.80
Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine (2003) 0.80
Risk of second malignant neoplasm among patients with lymphoma. J Clin Oncol (2011) 0.80
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer (2012) 0.80
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. Hormones (Athens) (2013) 0.79
Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders. Neurobiol Dis (2013) 0.79
How cells respond to interferons. J Clin Oncol (2010) 0.79
Pitfalls of positron emission tomography for assessing relapse in Hodgkin's disease: a case report. Haematologica (2006) 0.79
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. Ann Hematol (2014) 0.78
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 0.78
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol (2004) 0.78
The role of ultrasound-guided aspiration biopsy of peripheral pulmonary nodules: our experience. Anticancer Res (2002) 0.78
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. J Neurooncol (2008) 0.78
Hypoglycemic syndrome in a patient with proinsulin-only secreting pancreatic adenoma (proinsulinoma). Case Rep Med (2011) 0.77
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med (2015) 0.77
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res (2009) 0.77
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation. J Thorac Cardiovasc Surg (2006) 0.77
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Future Oncol (2015) 0.76
From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol (2006) 0.76
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report. J Thorac Dis (2010) 0.76
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response? Leuk Res (2006) 0.76
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig Liver Dis (2013) 0.75
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients. Nutrition (2010) 0.75
Gene expression profiling does not identify molecular subgroup among nodal peripheral T-cell lymphomas. J Clin Oncol (2007) 0.75
Secondary Leukemia in a non-Hodgkin's Lymphoma Patient Presenting as Myeloid Sarcoma of the Breast. Case Rep Hematol (2011) 0.75
Interleukin-2 and lymphokine-activated killer cell therapy in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res (2007) 0.75
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer (2004) 0.75
An acute-leukaemia-like picture due to breast carcinoma cells. Lancet Oncol (2006) 0.75
Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine (2002) 0.75
Fatal delayed diagnosis in a patient with Falciparum malaria. Haematologica (2004) 0.75